Recent Company News

• 08:31 AM ET Oct 08, 2026
  

  Vir Biotechnology announces FDA Fast Track designation to VIR-5500 for the treatment of prostate cancer ($11.52, 0.00)

• 08:27 AM ET Oct 02, 2026
  

  Astellas Pharma presents preliminary data from phase 4 OPTION-VMS for vasomotor symptoms (¥2245.0000, 0)

• 07:34 PM ET Sep 23, 2026
  

  Astellas Pharma reports first patient dosed in Phase 3 Study of setidegrasib in previously treated KRAS G12D-Mutated Advanced NSCLC (¥2383.5000, 0)

• 08:39 AM ET Sep 18, 2026
  

  StreetAccount Sector Summary - Healthcare Pre-Market

• 08:02 AM ET Sep 18, 2026
  

  EMA CHMP publishes summary of opinions for September 2026 meeting

• 06:37 AM ET Sep 18, 2026
  

  EU's CHMP adopted a positive opinion, recommending a change to the terms of the marketing authorisation for the medicinal product Padcev (¥2383.5000, 0)

• 08:15 AM ET Sep 16, 2026
  

  Sling Therapeutics (private) announces start of pivotal phase 3 trial for Thyroid Eye Disease (7:05ET) (¥2313.5000, 0)

• 01:09 AM ET Sep 09, 2026
  

  UCB's CIMZIA receives FDA Breakthrough Therapy designation for antiphospholipid syndrome (APS) in pregnant women (€206.90, 0.00)

• 08:33 AM ET Sep 01, 2026
  

  StreetAccount Themes Headlines (1-Sep)

• 05:26 PM ET Aug 31, 2026
  

  StreetAccount Sector Summary - Healthcare Post-Market